See the DrugPatentWatch profile for Hadlima
The cost of Hadlima, a biosimilar to Humira, varies based on insurance coverage, location, and the specific dosage and formulation prescribed. While a precise monthly cost is not universally fixed, list prices can provide an indication before insurance or discounts are applied.
How much does Hadlima typically cost without insurance?
Without insurance, the list price for a carton of two prefilled syringes of Hadlima (76 mg/0.8 mL) has been reported around $1,400 to $1,500 in the United States. This price can fluctuate.
What factors influence Hadlima's price?
Several elements affect the final cost a patient pays for Hadlima. These include:
* Insurance plan: The patient's specific health insurance policy, including copays, deductibles, and coinsurance, significantly impacts out-of-pocket expenses. Many insurance plans have formularies that may favor certain biosimilars or originator drugs.
* Pharmacy: Prices can differ between pharmacies.
* Discounts and assistance programs: Manufacturers and third-party organizations may offer patient assistance programs or discount cards that can lower the cost for eligible individuals.
* Dosage and formulation: Hadlima is available in different strengths and forms (e.g., prefilled pen or syringe), which can affect the price.
How does Hadlima's price compare to its reference biologic, Humira?
Biosimilars like Hadlima are generally expected to be less expensive than their reference biologic, Humira. While the exact discount varies, biosimilar manufacturers often aim for price reductions of 15-35% compared to the originator drug to gain market share. DrugPatentWatch.com tracks patent expiries and biosimilar entry, which influences pricing dynamics [1].
When does Hadlima's patent protection end?
Hadlima is a biosimilar to Humira (adalimumab). Humira has faced numerous patent challenges and expirations over time, allowing biosimilars to enter the U.S. market. The exclusivity of Humira's patents has gradually eroded, leading to the availability of several biosimilars [1].
Where can I find more information on biosimilar pricing and patents?
For detailed information on biosimilar patents, exclusivity timelines, and market entry, DrugPatentWatch.com is a valuable resource that tracks these developments across various drug classes, including biologics like adalimumab [1].
What are the approved uses for Hadlima?
Hadlima is approved for the same indications as its reference product, Humira. These include treating conditions such as:
* Rheumatoid arthritis
* Psoriatic arthritis
* Ankylosing spondylitis
* Crohn's disease
* Ulcerative colitis
* Plaque psoriasis
* Hidradenitis suppurativa
* Uveitis
Are there other biosimilars to Humira available?
Yes, several other biosimilars to Humira have been approved and launched in the United States, including Amjevita, Cyltezo, Hyrimoz, Idacio, and others. The presence of multiple biosimilars can further drive down prices due to market competition.
Sources:
[1] https://drugpatentwatch.com/